To our best knowledge, this is the first study analyzing the combination of CSF concentrations of lipid metabolism-related biomarkers, such as FABP3 and ApoE4 proteins with CSF levels of neurochemical dementia biomarkers (NDD). This evidence concerns the gene APOE and Neurodevelopmental delay.